Human Tissue Kallikreins-Related Peptidases Are Targets for the Treatment of Skin Desquamation Diseases.
inhibitor
kallikrein
serine protease
skin desquamation
skin disease
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
09
2021
accepted:
22
11
2021
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Human tissue Kallikrein-related peptidases (hKLKs) are serine proteases distributed in several tissues that are involved in several biological processes. In skin, many are responsible for skin desquamation in the Stratum Corneum (SC) of the epidermis, specially hKLK5, hKLK7, hKLK6, hKLK8, and hKLK14. In SC, hKLKs cleave proteins of corneodesmosomes, an important structure responsible to maintain corneocytes attached. As part of skin desquamation, hKLKs are also involved in skin diseases with abnormal desquamation and inflammation, such as Atopic Dermatitis (AD), psoriasis, and the rare disease Netherton Syndrome (NS). Many studies point to hKLK overexpression or overactive in skin diseases, and they are also part of the natural skin inflammation process, through the PAR2 cleavage pathway. Therefore, the control of hKLK activity may offer successful treatments for skin diseases, improving the quality of life in patients. Diseases like AD, Psoriasis, and NS have an impact on social life, causing pain, itchy and mental disorders. In this review, we address the molecular mechanisms of skin desquamation, emphasizing the roles of human tissue Kallikrein-related peptidases, and the promising therapies targeting the inhibition of hKLKs.
Identifiants
pubmed: 35356049
doi: 10.3389/fmed.2021.777619
pmc: PMC8959125
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
777619Informations de copyright
Copyright © 2022 Zani, Sant'Ana, Tognato, Chagas and Puzer.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biol Chem. 2018 Sep 25;399(9):1099-1105
pubmed: 29498930
J Biol Chem. 2001 Sep 7;276(36):33293-6
pubmed: 11435447
Bioorg Med Chem Lett. 2011 Oct 15;21(20):6112-5
pubmed: 21903387
Int J Dermatol. 2020 Apr;59(4):e75-e91
pubmed: 31930494
J Investig Dermatol Symp Proc. 2011 Dec;15(1):12-5
pubmed: 22076322
J Dermatol Sci. 2019 Aug;95(2):50-55
pubmed: 31279501
Biochem Biophys Res Commun. 2000 Sep 16;276(1):125-33
pubmed: 11006094
J Dermatol Sci. 2019 Jul;95(1):28-35
pubmed: 31255470
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2368-2372
pubmed: 32170896
Bioorg Med Chem Lett. 2018 May 1;28(8):1371-1375
pubmed: 29550094
J Biol Chem. 2007 Feb 9;282(6):3640-52
pubmed: 17158887
Am J Manag Care. 2017 Jun;23(8 Suppl):S115-S123
pubmed: 28978208
Br J Dermatol. 2007 May;156(5):875-83
pubmed: 17459012
Bioorg Med Chem Lett. 2019 May 1;29(9):1094-1098
pubmed: 30833107
J Exp Med. 2009 May 11;206(5):1135-47
pubmed: 19414552
Facial Plast Surg Clin North Am. 2017 Aug;25(3):283-289
pubmed: 28676156
J Invest Dermatol. 2012 Jun;132(6):1717-24
pubmed: 22358061
Cell Growth Differ. 1997 Jul;8(7):743-9
pubmed: 9218868
Am J Hum Genet. 2000 Mar;66(3):914-21
pubmed: 10712206
J Dermatol. 2018 Sep;45(9):1044-1052
pubmed: 29863755
J Invest Dermatol. 2010 May;130(5):1297-306
pubmed: 20090765
Acta Med Port. 2019 Sep 2;32(9):606-613
pubmed: 31493365
Mol Diagn Ther. 2017 Apr;21(2):137-152
pubmed: 27905021
Vet Dermatol. 2013 Feb;24(1):60-72.e15-6
pubmed: 23331681
Nat Med. 2007 Aug;13(8):975-80
pubmed: 17676051
J Biol Chem. 2007 Feb 23;282(8):5834-41
pubmed: 17182622
J Invest Dermatol. 2006 Oct;126(10):2338-42
pubmed: 16778802
J Biol Chem. 1996 Sep 6;271(36):21886-90
pubmed: 8702990
Dis Markers. 2015;2015:946572
pubmed: 26783378
J Invest Dermatol. 1994 Feb;102(2):145-9
pubmed: 8106745
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
J Exp Med. 2014 Mar 10;211(3):499-513
pubmed: 24534191
Br J Dermatol. 2014 Oct;171(4):760-70
pubmed: 24815089
J Med Chem. 2015 Jan 22;58(2):598-612
pubmed: 25489658
Acta Derm Venereol. 2007;87(6):499-505
pubmed: 17989887
Hum Pathol. 2011 Mar;42(3):409-18
pubmed: 21193224
Biomed Res Int. 2014;2014:526341
pubmed: 24809052
J Invest Dermatol. 2006 Jul;126(7):1609-21
pubmed: 16601670
APMIS. 2003 Jul-Aug;111(7-8):797-804
pubmed: 12974781
Arch Immunol Ther Exp (Warsz). 2009 Sep-Oct;57(5):345-54
pubmed: 19688185
PLoS One. 2012;7(7):e40443
pubmed: 22792325
Pediatr Dermatol. 1999 Jan-Feb;16(1):19-22
pubmed: 10027993
Int J Mol Sci. 2017 Dec 11;18(12):
pubmed: 29232931
J Invest Dermatol. 2011 Mar;131(3):688-97
pubmed: 21107351
PLoS One. 2016 Nov 8;11(11):e0166268
pubmed: 27824929
J Invest Dermatol. 2006 Feb;126(2):315-24
pubmed: 16374478
Mol Biol Cell. 2007 Sep;18(9):3607-19
pubmed: 17596512
Bioorg Med Chem Lett. 2019 Jan 15;29(2):334-338
pubmed: 30522951
J Invest Dermatol. 2004 Jul;123(1):62-6
pubmed: 15191543
Int J Cosmet Sci. 2012 Aug;34(4):298-306
pubmed: 22515370
N Engl J Med. 2011 Oct 6;365(14):1315-27
pubmed: 21991953
Hum Mol Genet. 2012 Oct 1;21(19):4187-200
pubmed: 22730493
J Invest Dermatol. 2008 Jan;128(1):18-25
pubmed: 17625593
J Allergy Clin Immunol. 2016 Jul;138(1):150-161.e13
pubmed: 26993035
Toxicol Appl Pharmacol. 2004 Mar 15;195(3):288-97
pubmed: 15020191
PLoS Genet. 2017 Jan 17;13(1):e1006566
pubmed: 28095415
Exp Dermatol. 2012 Sep;21(9):643-9
pubmed: 22507538
Exp Dermatol. 2007 Jun;16(6):513-9
pubmed: 17518992
Br J Dermatol. 2016 Aug;175(2):417-21
pubmed: 26920094
Bioorg Med Chem Lett. 2020 Dec 1;30(23):127626
pubmed: 33096161
J Biol Chem. 2006 Oct 27;281(43):32095-112
pubmed: 16885167
Crit Rev Clin Lab Sci. 2014 Apr;51(2):63-84
pubmed: 24490956
J Mol Biol. 2007 Nov 2;373(4):1017-31
pubmed: 17881000
Hum Gene Ther. 2019 Sep;30(9):1067-1078
pubmed: 31288584
Peptides. 2013 Dec;50:55-95
pubmed: 24126281
J Invest Dermatol. 2004 May;122(5):1235-44
pubmed: 15140227
Nat Genet. 2000 Jun;25(2):141-2
pubmed: 10835624
Molecules. 2017 Oct 27;22(11):
pubmed: 29077044
Int Immunol. 2015 Jun;27(6):269-80
pubmed: 25813515
Carcinogenesis. 2018 Dec 31;39(12):1529-1536
pubmed: 30137206
Int J Dermatol. 2011 Jan;50(1):102-13
pubmed: 21182510
Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51
pubmed: 23849879
J Am Soc Nephrol. 2005 Dec;16(12):3742-7
pubmed: 16251241
J Invest Dermatol. 2007 Sep;127(9):2228-35
pubmed: 17611580
Cell Tissue Res. 2013 Feb;351(2):289-300
pubmed: 23344365
J Cosmet Dermatol. 2007 Jun;6(2):75-82
pubmed: 17524122
Vet Immunol Immunopathol. 2002 Sep 6;88(1-2):1-12
pubmed: 12088639
J Dermatol. 2020 Mar;47(3):311-313
pubmed: 31912553
Orphanet J Rare Dis. 2018 Nov 26;13(1):213
pubmed: 30477583
Br J Dermatol. 2017 Jun;176(6):1525-1532
pubmed: 27797397
Expert Rev Mol Diagn. 2014 Jul;14(6):713-22
pubmed: 24927162
ACS Med Chem Lett. 2013 Dec 06;5(2):128-32
pubmed: 24900785
BMC Med Genomics. 2011 Oct 27;4:76
pubmed: 22032772
J Allergy Clin Immunol. 2009 Sep;124(3):536-43
pubmed: 19683336
Crit Rev Clin Lab Sci. 2021 Jan;58(1):1-16
pubmed: 32568598
Int J Dermatol. 2012 Apr;51(4):389-95; quiz 395-8
pubmed: 22435425
J Invest Dermatol. 2014 Jun;134(6):1665-1674
pubmed: 24390132
Clin Dermatol. 2012 May-Jun;30(3):257-62
pubmed: 22507037
Chem Rev. 2002 Dec;102(12):4751-804
pubmed: 12475206
Nutrients. 2018 Feb 11;10(2):
pubmed: 29439479
Dis Model Mech. 2020 Jun 1;13(5):
pubmed: 32457102
FASEB J. 2006 Oct;20(12):2068-80
pubmed: 17012259
Eur J Med Chem. 2015 Mar 26;93:202-13
pubmed: 25682203
Nat Genet. 2006 Apr;38(4):441-6
pubmed: 16550169
Int J Mol Sci. 2019 Mar 23;20(6):
pubmed: 30909615
Acta Derm Venereol. 2017 May 8;97(5):564-570
pubmed: 27958613